I-MAB-SPONSORED ADR (IMAB)

I-MAB Filed 2023 Annual Report on Form 20-F

/PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential...

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

/PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly...

I-Mab Announces Closing of the Divestiture of Business Operations in China

/PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential...

I-Mab Reports Full Year 2023 Financial Results and Business Update

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to...

I-Mab stock dips on plans to divest Chinese assets

I-Mab (IMAB) plans to divest its assets and business operations in China as it aims to become a US-based biotech amid rising geopolitical concerns. Read more here.

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Agreement marks an important milestone to advance the Company's intent to become a U.S.-based biotech Agreement provides for a strategic focus in advancing...

I-Mab gains FDA breakthrough tag for kidney disease therapy

I-Mab (IMAB) wins FDA breakthrough therapy status for its CD38-targeting monoclonal antibody felzartamab to treat primary membranous nephropathy. Read more here.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories!

7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole

There are some solid biotech stocks on the market. But there are many more that deserve an “F” rating from the Portfolio Grader.

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients' immune system against cancer cells....

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

Why Is TRACON Pharma (TCON) Stock Down 51% Today?

TRACON Pharmaceuticals (TCON) stock is falling on Tuesday morning following an update on a legal battle with I-Mab (IMAB).

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we check out the latest news worth watching on Tuesday!

Tracon stock falls after I-Mab gets favorable ruling in arbitration

I-Mab (IMAB) said an arbitration tribunal awarded no damages to Tracon Pharmaceuticals (TCON) related to a collaboration agreement. Read more here

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon's...

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting...

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

I-Mab Becomes Oversold (IMAB)

MSCI ESG Updated I-Mab to "A" Rating

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...